# A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)

Study · id `cardio:ct-nct02749994` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02749994](<https://clinicaltrials.gov/study/NCT02749994>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02749994

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 396 participants.

## Technical summary

Registry record NCT02749994. Randomized; double masking; primary purpose treatment. Start 2016-04 (registry gives no type); primary completion 2017-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 396 participants (enrolled count; ClinicalTrials.gov record NCT02749994, source copy `cardio:ctgov-nct02749994-2018-06-13`, retrieved 2026-10-31)
- Start date: 2016-04 (registry gives no type) (ClinicalTrials.gov record NCT02749994, source copy `cardio:ctgov-nct02749994-2018-06-13`, retrieved 2026-10-31)
- Primary completion: 2017-02 (actual) (ClinicalTrials.gov record NCT02749994, source copy `cardio:ctgov-nct02749994-2018-06-13`, retrieved 2026-10-31)
- Completion: 2017-02 (actual) (ClinicalTrials.gov record NCT02749994, source copy `cardio:ctgov-nct02749994-2018-06-13`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT02749994, source copy `cardio:ctgov-nct02749994-2018-06-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02749994-2018-06-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)
- Acronym: I-ROSETTE
- Condition: Hypercholesterolemia
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): Ezetimibe
- Lead sponsor: IlDong Pharmaceutical Co Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry lists this organization as the lead sponsor: IlDong Pharmaceutical Co Ltd (`cardio:org-ildong-pharmaceutical-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial (`cardio:pubmed-29402522`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 70a41371053ed5eb4fe987acd128f9fdee186480065aef5a6ccb1a1ef36842e9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
